The Michael Glickman Lab

The Michael Glickman Lab

We are broadly interested in the biology of mycobacteria, which include the major human pathogen M. tuberculosis, the nonpathogenic model organism M. smegmatis, and the cancer biotherapeutic agent BCG.

Learn more
Pictured: Michael Glickman

Michael S. Glickman, MD


Research Focus

Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including regulated intramembrane proteolysis (the Rip1 pathway); double-strand-break repair and associated DNA damage responses; and cell envelope biosynthesis.


MD, Columbia University College of Physicians and Surgeons


  • Redelman-Sidi, G., Iyer, G., Solit, D., and Glickman, M.S. Oncogenic activation of Pak1 dependent Macropinocytosis pathway determines BCG entry into bladder cancer cells. Cancer Res. 2013 Feb 1;73(3):1156-67.
  • Jessica S Schneider, Shilpa R Reddy , Hock Y E , Henry Evans , Michael S. Glickman. Site-2 protease substrate specificity and coupling in trans by a PDZ-substrate adapter protein. Proc Natl Acad Sci U S A 2013 Nov 26;110(48):19543-8.
Learn more